ACT Brief: Policy Shifts, FDA Inspections, and Tariffs Pose New Challenges for Clinical Trials

In this episode of the ACT Brief, we spotlight an earlier interview with Ron Lanton, partner at Lanton Law, in which he discussed how rising drug costs, reduced FDA inspections, and potential tariffs on active pharmaceutical ingredients could increase costs and slow progress across the clinical research landscape.